Published in Int J Gynecol Pathol on April 01, 2004
My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol (2006) 1.22
Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol Oncol (2013) 1.02
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol (2012) 0.95
Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch (2010) 0.92
The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol (2013) 0.91
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance. Virchows Arch (2010) 0.84
Glut-1 Expression Correlates with Basal-like Breast Cancer. Transl Oncol (2011) 0.80
P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin Exp Metastasis (2007) 0.78
p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer. Saudi J Gastroenterol (2013) 0.78
Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer. Cancer Sci (2017) 0.76
Practical issues in the diagnosis of serous carcinoma of the endometrium. Mod Pathol (2016) 0.75
Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas. Appl Immunohistochem Mol Morphol (2016) 0.75
Could immunohistochemistry for p53 help tailor surgical treatment in endometrial carcinoma? Int J Gynecol Pathol (2004) 0.75
Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. Virchows Arch (2017) 0.75
Allelic loss at TP53 in metastatic human endometrial carcinomas. Clin Exp Metastasis (2009) 0.75
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 5.58
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol (2011) 4.66
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics (2010) 4.02
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol (2006) 3.53
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol (2006) 3.42
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Osteopontin expression correlates with melanoma invasion. J Invest Dermatol (2005) 3.13
Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol (2002) 3.11
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA (2013) 3.06
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol (2009) 2.22
Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst (2009) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A (2006) 2.08
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol (2010) 2.04
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol (2009) 2.04
Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer (2008) 2.01
Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol (2005) 1.94
Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol (2013) 1.94
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res (2004) 1.90
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol (2010) 1.87
Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol (2012) 1.86
The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest (2008) 1.85
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res (2011) 1.79
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat (2007) 1.75
Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. Protein Sci (2005) 1.73
Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res (2008) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. J Pathol (2012) 1.72
Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol (2011) 1.72
Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol (2002) 1.67
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res (2004) 1.67
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol (2009) 1.67
Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol (2002) 1.60
The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer (2009) 1.60
Gastric cancer: new genetic developments. J Surg Oncol (2005) 1.55
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol (2003) 1.49
Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol (2009) 1.48
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res (2006) 1.47
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol (2013) 1.47
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat (2002) 1.44
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer (2009) 1.43
Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol (2005) 1.42
Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol (2010) 1.42
Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet (2003) 1.42
Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet (2009) 1.39
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res (2010) 1.38
Targeted transcriptional repression of Gfi1 by GFI1 and GFI1B in lymphoid cells. Nucleic Acids Res (2004) 1.34
IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol (2009) 1.33
Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol (2005) 1.33
Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol (2008) 1.32
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat (2007) 1.30
Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol (2010) 1.29
Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. Cancer Res (2004) 1.29
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol (2010) 1.28
The origin of ovarian carcinomas: a developmental view. Gynecol Oncol (2008) 1.26
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res (2008) 1.25
The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol (2012) 1.23
Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol (2010) 1.23
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev (2013) 1.22
Estimating cancer prevalence using mixture models for cancer survival. Stat Med (2002) 1.21
Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology (2009) 1.21
Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J Mol Histol (2007) 1.20
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol (2008) 1.20